Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Tathmini ya Mgonjwa ya Ubora wa Maisha Kuhusu Kuvimbiwa× | Fahirisi ya Dalili Muhimu za Gastroparesis× | Vigezo vya Utambuzi vya Rome IV kwa Ugonjwa wa Utumbo unaowashwawashwa× | Kifupi cha Dodoso la Magonjwa ya Kuvimba Utumbo× | |
|---|---|---|---|---|
| Nyanja | Gastroenterolojia | Gastroenterolojia | Gastroenterolojia | Gastroenterolojia |
| Familia | Process / pipeline | Process / pipeline | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2005 | 2003 | 2016 | 2004 |
| Mwanzilishi≠ | Marquis, P., De La Loge, C., Dubois, D., et al. | Revicki, D. A., Rentz, A. M., Dubois, D., et al. | Rome Foundation (multinational expert consensus) | Guyonnet, D., Chassany, O., Ducroc, R., et al. |
| Aina≠ | Self-report | Self-report | Diagnostic Criteria | Self-report |
| Chanzo asilia≠ | Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005). Development and validation of the Patient Assessment of Constipation-Quality of Life questionnaire. Scandinavian Journal of Gastroenterology, 40(5), 540–551. DOI ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ | Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation. link ↗ | Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465. link ↗ |
| Majina mbadala≠ | PAC-QoL, PAC-Q | GCSI | Rome IV IBS, Rome Criteria | IBDQ-32, Short IBDQ |
| Zinazohusiana | 4 | 4 | 4 | 4 |
| Muhtasari≠ | The Patient Assessment of Constipation Quality of Life (PAC-QoL) is a validated, patient-reported outcome measure designed to assess the impact of functional constipation on physical, psychological, and social well-being. Developed by Marquis and colleagues in 2005, the PAC-QoL comprises 28 items organized into four domains: Physical Discomfort, Psychosocial Discomfort, Worries and Concerns, and Satisfaction. The PAC-QoL is responsive to treatment and widely used in constipation clinical trials and practice. | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. | The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns. | The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice. |
| ScholarGateSeti ya data ↗ |
|
|
|
|